How does the divestiture fit with ABC's new alliance with Walgreens and Alliance Boots?
Following its dramatic alignment with Walgreens and Alliance Boots, AmerisourceBergen Corp. (Valley Forge, PA) has announced the sale of its Canadian distribution assets (but not its specialty-related businesses) to Kohl & Frisch Ltd, a Canadian full-line distributor. The deal, worth between $80-$100 million, will be partially financed by ABC, which also says the sale will result in an impairment charge of $160-180 million in Q2 2013 statement. ABC hinted at less-than stellar performance from the unit in its end-of-Q1 statement, saying that results were impacted by “disappointing performance in our Canadian distribution business.” With the divestiture, ABC expects better earnings for the current fiscal year, raising its earnings estimate by 8-10 cts per share.
On March 19, ABC and Walgreens announced a 10-year supply agreement; with Walgreens’ existing relationship with Alliance Boots, and with an investment in ABC by those companies, a multinational drug-distribution and —retailing juggernaut is being formed. Interestingly, neither of ABC’s new partners has a substantial stake in Canada and so, even though global distribution and retailing is the promise of the alignment, Canada won’t be part of that for the foreseeable future. A contributing factor might also be a new effort by Canadian provinces to rein in generic drug prices, which studies have shown tend to be higher than in other nations.
In late 2012, ABC also announced a planned divestiture of AndersonBrecon, a contract packaging business it has grown by combining its Anderson Packaging unit (Rockford, IL) with Brecon Packaging (Herefordshire, UK). No buyer has yet come forward.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.